Literature DB >> 35732992

Generation of CAR-T Cells with Sleeping Beauty Transposon Gene Transfer.

Sabrina Prommersberger1, Razieh Monjezi1, Lacramioara Botezatu2, Csaba Miskey2, Maximilian Amberger2, Michael Hudecek1, Zoltán Ivics3, Katrin Mestermann1.   

Abstract

Human T lymphocytes that transgenically express a chimeric antigen receptor (CAR) have proven efficacy and safety in gene- and cell-based immunotherapy of certain hematological cancers. Appropriate gene vectors and methods of genetic engineering are required for therapeutic cell products to be biologically potent and their manufacturing to be economically viable. Transposon-based gene transfer satisfies these needs, and is currently being evaluated in clinical trials. In this protocol we describe the basic Sleeping Beauty (SB) transposon vector components required for stable gene integration in human cells, with special emphasis on minicircle DNA vectors and the use of synthetic mRNA. We provide a protocol for functional validation of the vector components in cultured human cell lines on the basis of fluorescent reporter gene expression. Finally, we provide a protocol for CAR-T cell engineering and describe assays that address transgene expression, biological potency and genomic vector copy numbers in polyclonal cell populations. Because transposons allow virus-free gene transfer with naked nucleic acids, the protocol can be adopted by any laboratory equipped with biological safety level S1 facilities.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Adoptive cell therapy; Cancer; Chimeric antigen receptor; Gene transfer; Genetic vectors; Genomic integration; Immunotherapy; Transposon; Vector copy number

Mesh:

Substances:

Year:  2022        PMID: 35732992     DOI: 10.1007/978-1-0716-2441-8_3

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  1 in total

1.  Parkinson disease repurposing promise.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2017-09-29       Impact factor: 84.694

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.